The National Cancer Institute (NCI) of the Department of Health and Human Services is issuing a funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer." This initiative aims to enhance the validation and adoption of various biomarkers and assays used in cancer detection, diagnosis, and treatment response prediction. The funding opportunity (PAR-25-075) supports projects that work with established assays that have been analytically validated for clinical use, allowing collaboration among scientific experts. Key objectives include clinical validation of markers that can influence treatment strategies and efforts to standardize assays across different laboratories. Applications must demonstrate adequate preliminary data on assays and their clinical relevance. The maximum funding available is $250,000 per year for a three-year project period, and eligible applicants include various types of institutions and organizations with the experience and capabilities necessary for the project. The document outlines specific application requirements, timelines, and review criteria, emphasizing the importance of addressing significant gaps in cancer research and developing innovative and rigorous methodologies. The NCI will have substantial involvement post-award, guiding the funded projects to successful outcomes focused on improving cancer diagnostics and therapeutics.